(Q37807779)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Pediatric nonalcoholic fatty liver disease: a comprehensive review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Jeffrey B. Schwimmer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

7

Perrie E Pardee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Sarah M Lindbäck

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Charles Gabbert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Benjamin L Johnson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Emmanuil Smorodinsky

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Natalie Garcia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Kristin D Kistler

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

published in

Advances in pediatrics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

85-140

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

Pathology of fatty liver disease

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic steatohepatitis: definition and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Fine structure of hepatocytes during the etiology of several common pathologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Histopathology of pediatric nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Clinical and histological features of nonalcoholic fatty liver disease in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The role of hepatic biopsy to detect macrovacuolar steatosis during liver procurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Complications of percutaneous abdominal fine-needle biopsy. Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Cell death: critical control points

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Ultrasonographical Diagnosis of Fatty Liver: Significance of the Liver-Kidney Contrast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Sonographic diagnosis of diffuse liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Imaging of hepatic steatosis and fatty sparing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The utility of radiological imaging in nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

MRI and ultrasound for hepatic fat quantification:relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Interobserver and intraobserver variability in the sonographic assessment of fatty liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Computed tomography attenuation values in fatty liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Fatty liver: imaging patterns and pitfalls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Imaging of hepatic steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Non-invasive means of measuring hepatic fat content.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Quantification of liver fat using magnetic resonance spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Advanced MRI methods for assessment of chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Simple proton spectroscopic imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Noninvasive imaging biomarkers for steatosis assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Noninvasive assessment of hepatic steatosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging--correlation with histopathologic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Introduction of fast MR imaging in the assessment of hepatic steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Relaxation effects in the quantification of fat using gradient echo imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

MR imaging of fat-containing tissues: valuation of two quantitative imaging techniques in comparison with localized proton spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

T1 independent, T2* corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Elastic modulus measurements of human liver and correlation with pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Cirrhosis: MR imaging features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Magnetic resonance imaging of diffuse liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Cirrhosis: CT and MR imaging evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

MR imaging of liver fibrosis: current state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Chronic hepatitis: correlation of early patchy and late linear enhancement patterns on gadolinium-enhanced MR images with histopathology initial experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Emergence of different macrophage populations in hepatic fibrosis following thioacetamide-induced acute hepatocyte injury in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Measurement of liver stiffness with two imaging techniques: magnetic resonance elastography and ultrasound elastometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

MR elastography of the liver: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Assessment of hepatic fibrosis with magnetic resonance elastography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Insulin resistance--mechanisms, syndromes, and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hyperinsulinemia in obesity syndromes: its metabolic consequences and possible etiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Non-alcoholic fatty liver disease from pathogenesis to management: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Kupffer cells mediate leptin-induced liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Prevalence of fatty liver in children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Heritability of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Characterization of the human patatin-like phospholipase family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The relationship between fatty liver and hyperinsulinemia in obese Japanese children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease in overweight children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or =95th percentile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Predictors of non-alcoholic fatty liver disease in obese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Decreased prevalence of nonalcoholic fatty liver disease in black obese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease in children: a single center experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic Steatohepatitis in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A quantitative scale of acanthosis nigricans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Cytokines and renin-angiotensin system signaling in hepatic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Management of hypertension in children and adolescents with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Prevalence of overweight and obesity in the United States, 1999-2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Acute fatty liver disease after suprasellar tumor resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Pediatric nonalcoholic steatohepatitis associated with hypopituitarism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Non-alcoholic steatohepatitis and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Primary liver cancers with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Hepatocellular carcinoma arising in non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Long-term follow-up of patients with NAFLD and elevated liver enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease and carotid atherosclerosis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Effects of nonalcoholic fatty liver disease on the development of metabolic disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Metabolic and Nutritional Profile of Obese Adolescents With Nonalcoholic Fatty Liver Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Fructose consumption as a risk factor for non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Fructose and oxidized low-density lipoprotein in pediatric nonalcoholic fatty liver disease: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Treatment of nonalcoholic fatty liver disease in children: TONIC trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Effect of taurine on the fatty liver of children with simple obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

N-acetylcysteine in the treatment of non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Lipid screening and cardiovascular health in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Storm over statins--the controversy surrounding pharmacologic treatment of children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Short-term outcome in the first 10 morbidly obese adolescent patients in the FDA-approved trial for laparoscopic adjustable gastric banding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Best practice updates for pediatric/adolescent weight loss surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2010.08.006

10.1016/J.YAPD.2010.08.006

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21056736%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference